Twist Bioscience Co. (NASDAQ:TWST) COO Sells $97,426.49 in Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,261 shares of the firm’s stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $43.09, for a total transaction of $97,426.49. Following the transaction, the chief operating officer now directly owns 159,483 shares in the company, valued at $6,872,122.47. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total transaction of $296,636.65.
• On Monday, August 5th, Patrick John Finn sold 2,885 shares of Twist Bioscience stock. The shares were sold at an average price of $39.93, for a total transaction of $115,198.05.

Twist Bioscience Stock Performance

TWST stock traded up $0.36 during trading on Friday, reaching $40.60. The company had a trading volume of 593,422 shares, compared to its average volume of 955,359. The firm has a 50-day simple moving average of $43.89 and a 200-day simple moving average of $44.58. The company has a market cap of $2.36 billion, a price-to-earnings ratio of -12.08 and a beta of 1.77. Twist Bioscience Co. has a twelve month low of $14.42 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The firm’s revenue for the quarter was up 27.7% on a year-over-year basis. During the same quarter last year, the business earned ($1.01) earnings per share. Sell-side analysts expect that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Institutional Trading of Twist Bioscience

Institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets boosted its stake in Twist Bioscience by 34.8% in the 1st quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock worth $5,895,000 after purchasing an additional 44,349 shares in the last quarter. SageView Advisory Group LLC acquired a new stake in Twist Bioscience during the 1st quarter valued at approximately $1,144,000. Susquehanna Fundamental Investments LLC acquired a new stake in Twist Bioscience during the 1st quarter valued at approximately $300,000. Sei Investments Co. lifted its stake in Twist Bioscience by 32.7% during the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock valued at $7,670,000 after acquiring an additional 55,124 shares during the period. Finally, Silvercrest Asset Management Group LLC lifted its stake in Twist Bioscience by 38.6% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock valued at $4,605,000 after acquiring an additional 37,376 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms have commented on TWST. Robert W. Baird raised their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a report on Monday, August 5th. The Goldman Sachs Group raised their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Finally, Leerink Partners raised their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.